Richard J. Travers

Hematology

860 Washington St
Boston, MA 02111

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.

Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.

Journal: Circulation

Published: August 05, 2025

Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis.

Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis.

Journal: Blood vessels, thrombosis & hemostasis

Published: July 08, 2025

Permissive Cardiotoxicity and Determination of Anthracycline Risk With Previous Anthracycline Exposure.

Permissive Cardiotoxicity and Determination of Anthracycline Risk With Previous Anthracycline Exposure.

Journal: JACC. Case reports

Published: March 19, 2025

Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.

Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: August 15, 2024

Antipolyphosphate monoclonal antibodies derived from autoimmune mice.

Antipolyphosphate monoclonal antibodies derived from autoimmune mice.

Journal: Research and practice in thrombosis and haemostasis

Published: April 13, 2024

Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.

Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.

Journal: Clinical science (London, England : 1979)

Published: March 26, 2024

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.

Journal: PloS one

Published: June 08, 2023

ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity.

ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity.

Journal: JACC. CardioOncology

Published: October 10, 2022

VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.

VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.

Journal: Current oncology reports

Published: December 14, 2021

S100A9-RAGE Axis Accelerates Formation of Macrophage-Mediated Extracellular Vesicle Microcalcification in Diabetes Mellitus.

S100A9-RAGE Axis Accelerates Formation of Macrophage-Mediated Extracellular Vesicle Microcalcification in Diabetes Mellitus.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: May 29, 2020

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.

Journal: Blood advances

Published: August 26, 2016

Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.

Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.

Journal: Blood

Published: February 14, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026